Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Desmoteplase Approval For Stroke Expected In 2009, Forest Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Nine-hour treatment window could expand market. A Phase IIb/III dose-ranging study is underway. Desmoteplase is one of a handful of late-stage opportunities for Forest; the company will be in a quiet period in terms of product approvals until late in the decade.

You may also be interested in...



I Want To Thin Your Blood: Vampire Bat-Based Stroke Drug Trial Resumes

Potential safety signal in Forest/PAION’s desmoteplase study no longer spooks data monitoring committee.

I Want To Thin Your Blood: Vampire Bat-Based Stroke Drug Trial Resumes

Potential safety signal in Forest/PAION’s desmoteplase study no longer spooks data monitoring committee.

Forest’s Desmoteplase Stroke Study Halted Due To Safety Signal

Company experiences second R&D setback this week.

Related Content

Topics

UsernamePublicRestriction

Register

LL1134025

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel